Seelos Therapeutics Inc. (NASDAQ:SEEL) traded with a subtraction of -$0.02 to close at $0.68 on Friday, a downside of -2.72 percent. An average of 758,767 shares of common stock have been traded in the last five days. There was a fall of -$0.0555 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 982,757 shares traded, while the 50-day average volume stands at 683,595.
SEEL stock has decreased by -9.24% in the last month. The company shares reached their 1-month lowest point of $0.6300 on 12/30/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.48 and a high of $1.73 in 52 weeks. It has reached a new high 1 time so far this year and lost -57.12% or -$0.9475 in price. In spite of this, the price is down -60.69% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Seelos Therapeutics Inc. (SEEL) stock’s beta is 2.01. Other valuation ratios to consider include the price-to-book (PB) ratio at 9.99.
The quick ratio of Seelos Therapeutics Inc. for the three months ended September 29 was 1.90, and the current ratio was 1.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.35 and a total debt to equity ratio of 2.71 for the quarter ending September 29. Its gross profit as reported stood at $61.67 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Seelos Therapeutics Inc.’s return on assets was -132.80%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$19.6 million in the quarter, while revenues of -$21.27 million were grew 44.8%. The analyst consensus anticipated Seelos Therapeutics Inc.’s latest quarter earnings to come in at -$0.1 per share, but it turned out to be -$0.18, a -80.00% surprise. For the quarter, EBITDA amounted to -$17.41 million. Shareholders own equity worth $107.17 million.
From a technical analysis perspective, let’s take a brief look at Seelos Therapeutics Inc. (SEEL) price momentum. RSI 9-day as of the close on 29 December was 34.66%, suggesting the stock is Neutral, with historical volatility in this time frame at 69.84%.
As of today, SEEL’s price is $0.6839 -7.52% or -$0.0555 from its 5-day moving average. SEEL is currently trading -32.43% lower than its 20-day SMA and -23.30% lower than its 100-day SMA. However, the stock’s current price level is -23.32% below the SMA50 and -24.00% below the SMA200.
The stochastic %K and %D were 4.81% and 3.10%, respectively, and the average true range (ATR) was 0.1142. With the 14-day stochastic at 6.82% and the average true range at 0.1135, the RSI (14) stands at 38.31%. The stock has reached -0.0214 on the 9-day MACD Oscillator while the 14-day reading was at -0.1838.
ROTH Capital upgraded Seelos Therapeutics Inc. (NASDAQ: SEEL) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral.